Locations:
Search IconSearch
August 1, 2016/Cancer/Research

August Cancer Clinical Trials

Learn about featured cancer clinical trials currently enrolling, or search our cancer clinical trials database for all open and accruing studies

clinical-trials-690-x-380

Breast
Phase III study evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy
GBG 1115 | 15-1373
View full trial information.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Esophageal
A Four Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel
HCP 2215 | 031520C
View full trial information.

Pancreas
A Phase II Study of Second-Line Therapy with Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer
CASE 5214 | 15-166
View full trial information.

Renal
A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab (Msb0010718c) In Combination With Axitinib (Inlyta®) Versus Sunitinib (Sutent®) Monotherapy In The First-Line Treatment Of Patients With Advanced Renal Cell Carcinoma
PFIZ 2816 | 16-573
View full trial information.

Solid Tumors
A Two Part, Phase 1, Multicenter, Open-label Study of TRX518 in Adults with Advanced Solid Tumors
GITR 1Y15 | 101506C
View full trial information.

Myelodysplastic Syndrome (MDS)
A Phase 3, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Placebo For the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes in Subjects With Ring Sideroblasts Who Require Red Blood Cell Transfusions
CLGN 2915 | 16-462
View full trial information.

Lymphoma, Diffuse Large B Cell
A Phase I/II Study of Carfilzomib in Combination with R-CHOP (CR-CHOP) for Patients with Diffuse Large B -Cell Lymphoma
CASE 3413 | 14-256
View full trial information.

Advertisement

Related Articles

DNA
October 10, 2024/Cancer/Research
Blocking YES1 Protein Resensitizes Triple-Negative Breast Cancer to Treatment

Obstructing key protein allows for increased treatment uptake for taxane chemotherapy

Hereditary Hemorrhagic Telangiectasia
September 23, 2024/Cancer/Research
Pomalidomide Effective in Treating Hereditary Hemorrhagic Telangiectasia

Oral medication reduces epistaxis and improves quality of life for patients with rare vascular disorder

Radiation therapy
September 17, 2024/Cancer/Research
ASTRO 2024 Highlights

A preview for radiation oncologists

Dr. Shilpa Gupta
September 16, 2024/Cancer/Research
New Studies Reinforce Benefits of Combination Treatment for Urothelial Carcinoma

Enfortumab vedotin plus pembrolizumab benefited patients, regardless of biomarker expression

Before and after scan
August 28, 2024/Cancer/Research
Case Study: Patient with Metastatic Urothelial Carcinoma Has No Remaining Evidence of Disease

Treatment involved checkpoint inhibitor, surgery and intravesical therapy

Dr. Maciejewski
August 23, 2024/Cancer/Research
Studies Evaluate Anti-Complement Inhibitors for Treating Paroxysmal Nocturnal Hemoglobinuria

Researchers Assess Real-Life Experiences of Patients Treated Outside of Clinical Trials

Dr. Raza
August 19, 2024/Cancer/Research
Understanding the Role of Palliative Care in AL Amyloidosis

Multi-specialty coordination essential for improving quality of life

Ad